Physician Data Query

Last uploaded: November 18, 2019
Preferred Name

auranofin

Synonyms

Ridaura

Definitions

An orally available, lipophilic, organogold compound, used to treat rheumatoid arthritis, with anti-inflammatory and potential antineoplastic activities. Auranofin interacts with selenocysteine residue within the redox-active domain of mitochondrial thioredoxin reductase (TrxR), thereby blocking the activity of TrxR. As a result, this agent induces mitochondrial oxidative stress leading to the induction of apoptosis. Furthermore, this agent strongly inhibits the JAK1/STAT3 signal transduction pathway, thereby suppressing expression of immune factors involved in inflammation. TrxR, overexpressed in many cancer cell types, inhibits apoptosis, promotes cell growth and survival and plays a role in resistance to chemotherapy; TrxR catalyzes the reduction of oxidized thioredoxin (Trx) and plays a central role in regulating cellular redox homeostasis. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C96801" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C96801" NCI Thesaurus)

ID

http://purl.bioontology.org/ontology/PDQ/CDR0000710355

altLabel

Ridaura

CAS Registry

34031-32-8

cui

C0004320

C0699923

DATE FIRST PUBLISHED

2011-08-24

Date last modified

2011-08-24

definition

An orally available, lipophilic, organogold compound, used to treat rheumatoid arthritis, with anti-inflammatory and potential antineoplastic activities. Auranofin interacts with selenocysteine residue within the redox-active domain of mitochondrial thioredoxin reductase (TrxR), thereby blocking the activity of TrxR. As a result, this agent induces mitochondrial oxidative stress leading to the induction of apoptosis. Furthermore, this agent strongly inhibits the JAK1/STAT3 signal transduction pathway, thereby suppressing expression of immune factors involved in inflammation. TrxR, overexpressed in many cancer cell types, inhibits apoptosis, promotes cell growth and survival and plays a role in resistance to chemotherapy; TrxR catalyzes the reduction of oxidized thioredoxin (Trx) and plays a central role in regulating cellular redox homeostasis. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C96801" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C96801" NCI Thesaurus)

LT

TRD

NCI ID

C96801

notation

CDR0000710355

ORIG STY

Drug/agent

prefLabel

auranofin

tui

T109

T121

Delete Subject Author Type Created
No notes to display
Create New Mapping

Delete Mapping To Ontology Source
http://phenomebrowser.net/ontologies/mesh/mesh.owl#D02.691.675.249.150 RH-MESH LOOM
http://purl.bioontology.org/ontology/RXNORM/1227 RXNORM CUI
http://purl.bioontology.org/ontology/RXNORM/1227 RXNORM LOOM
http://purl.bioontology.org/ontology/SNOMEDCT/387100001 SNOMEDCT CUI
http://purl.bioontology.org/ontology/SNOMEDCT/387100001 SNOMEDCT LOOM
http://evs.nci.nih.gov/ftp1/NDF-RT/NDF-RT.owl#N0000146358 ODAE LOOM
http://purl.bioontology.org/ontology/RXNORM/202952 RXNORM CUI
http://purl.obolibrary.org/obo/DRON_00013467 ODNAE LOOM
http://purl.obolibrary.org/obo/DRON_00013467 DRON LOOM
http://purl.bioontology.org/ontology/CSP/0729-8063 CRISP CUI
http://sbmi.uth.tmc.edu/ontology/ochv#C0004320 OCHV LOOM
http://purl.bioontology.org/ontology/NDFRT/N0000146358 NDFRT CUI
http://purl.bioontology.org/ontology/NDFRT/N0000146358 NDFRT LOOM
http://purl.bioontology.org/ontology/SNMI/C-B8210 SNMI CUI
http://purl.bioontology.org/ontology/SNMI/C-B8210 SNMI LOOM
http://sbmi.uth.tmc.edu/ontology/ochv#1593 OCHV LOOM
http://www.co-ode.org/ontologies/galen#Auranofin GALEN LOOM
http://purl.bioontology.org/ontology/UATC/M01CB03 ATC CUI
http://purl.bioontology.org/ontology/UATC/M01CB03 ATC LOOM
http://purl.bioontology.org/ontology/RCD/x02pb RCD CUI
http://purl.bioontology.org/ontology/SNOMEDCT/18002004 SNOMEDCT CUI
http://purl.bioontology.org/ontology/CSP/1439-4941 CRISP CUI
http://purl.bioontology.org/ontology/NDDF/002398 NDDF CUI
http://purl.bioontology.org/ontology/NDDF/002398 NDDF LOOM
http://purl.bioontology.org/ontology/SCTSPA/387100001 SCTSPA CUI
http://phenomebrowser.net/ontologies/mesh/mesh.owl#D001310 RH-MESH LOOM
http://purl.bioontology.org/ontology/SCTSPA/18002004 SCTSPA CUI
http://purl.bioontology.org/ontology/RCD/j56.. RCD CUI
http://purl.bioontology.org/ontology/RCD/j56.. RCD LOOM
http://purl.jp/bio/4/id/200906031675805988 IOBC LOOM
http://purl.obolibrary.org/obo/CHEBI_2922 BIOMODELS LOOM
http://purl.obolibrary.org/obo/CHEBI_2922 DINTO LOOM
http://purl.obolibrary.org/obo/CHEBI_2922 CHEBI LOOM
http://bmi.utah.edu/ontologies/peontology/C0004320 RAO LOOM
http://purl.bioontology.org/ontology/MESH/D001310 MESH CUI
http://purl.bioontology.org/ontology/MESH/D001310 MESH CUI
http://purl.bioontology.org/ontology/MESH/D001310 MESH LOOM
http://purl.bioontology.org/ontology/NDFRT/N0000007406 NDFRT CUI
http://purl.bioontology.org/ontology/VANDF/4018014 VANDF CUI
http://purl.bioontology.org/ontology/VANDF/4018014 VANDF LOOM
http://www.drugbank.ca/drugs/DB00995 FTC LOOM
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C65242 NCIT LOOM
http://purl.bioontology.org/ontology/MSHFRE/D001310 MSHFRE CUI